Megamarket Liquid Biopsy: Guardant Health Emerges as a Winner Stock!

I've been discussing Guardant Health extensively in the Tenbagger Forum since early 2020. Back then, the stock was trading around $20. The stock is speculative, but the market potential is enormous. The company is a pioneer in the field of liquid biopsy, employing innovative blood tests for cancer diagnostics, therapy selection, monitoring, and early detection. In the third quarter, Guardant achieved a significant milestone: the company surpassed an annual revenue rate of over $1 billion for the first time and exceeded expectations with a revenue...